GET DAILY SIGNALSHarmony Biosciences (HRMY) Declines -13.8% Over 30 Days Amid Leadership Shift
Key Takeaways
- Harmony Biosciences (HRMY) has declined roughly 13.8% over the last 30 days, falling from a closing price of $39.92 on October 5, 2026, to an intraday level near $34.42 in early November.
- Over the last quarter, the stock is down about 11%, retreating from levels around $38.78 in early August after peaking near $43 in early September.
- A planned CEO transition announced on October 12, 2026, triggered a sell-off of more than 5% in a single session despite reaffirmed full-year revenue guidance.
- Third-quarter 2026 results reported in early November showed WAKIX net revenue of $268.9 million, up 12% year over year, but slightly below consensus and paired with a year-over-year decline in earnings per share.
- Broader weakness across the pharmaceuticals sector and a mixed analyst landscape, including Sell and Hold ratings with lower price targets, added pressure during the period.
Harmony Biosciences (HRMY) Company Overview and Market Position
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company headquartered in Plymouth Meeting, Pennsylvania, focused on developing and commercializing therapies for patients living with rare neurological diseases. Its lead product, WAKIX (pitolisant), is the first and only FDA-approved, non-scheduled treatment for excessive daytime sleepiness and cataplexy in adults and pediatric patients six years and older with narcolepsy.
WAKIX has become the company's flagship commercial asset, with Harmony targeting more than $1 billion in full-year 2026 net revenue. Beyond WAKIX, the company is advancing a neuroscience pipeline led by BP-205, an investigational orexin-2 receptor agonist, along with lifecycle programs for pitolisant and other rare-CNS assets. Investors follow HRMY closely because of the durability of the WAKIX franchise, the pipeline's long-term potential, and the company's sizable cash position, which supports strategic business development. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Harmony Biosciences (HRMY) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, HRMY shares have fallen approximately 13.8%. The stock closed at $39.92 on October 5, 2026, and traded near $34.42 by early November, reflecting a steady downward drift punctuated by sharper single-day declines in mid-October and again in early November.
The quarterly picture is similarly negative but less severe. From a close near $38.78 on August 4, 2026, the stock is down roughly 11% over the trailing three months. Notably, the quarter included a strong early stretch: HRMY climbed to an intraday high above $43 in early September before momentum reversed. The subsequent pullback, driven by leadership-change headlines, sector rotation, and a softer earnings reaction, has left shares well below their late-summer peak.
What Drove HRMY Stock Price in the Last 30 Days
The most consequential catalyst of the period was the October 12, 2026, announcement of a planned leadership transition. The company said President and CEO Jeffrey M. Dayno, M.D., would retire at the end of 2026, with COO Peter Anastasiou set to become CEO effective January 1, 2027. Although Harmony characterized the move as a planned succession and reaffirmed its 2026 WAKIX revenue guidance of $1.0 billion to $1.04 billion, investors reacted negatively, sending shares down more than 5% that session.
Weakness in late October was compounded by broad declines across the pharmaceuticals sub-sector, with HRMY closing near session lows during a period of market-wide selling pressure. The final leg lower arrived with third-quarter 2026 results reported on November 4, 2026. WAKIX net revenue of $268.9 million grew 12% year over year, but it came in modestly below analyst expectations, while net income declined to $48.2 million, or $0.81 per diluted share, from $50.9 million, or $0.87 per share, a year earlier, partly reflecting higher royalty and milestone costs.
Analyst sentiment also remained divided. While several firms maintained Buy or Outperform ratings, Bank of America Securities reiterated a Sell rating with a $30 price target, and other institutions maintained Hold ratings with price targets near or below the prevailing share price, reinforcing a cautious near-term tone.
What Drove HRMY Stock Performance Over the Last Quarter
The broader three-month narrative reflects a stock that rallied early and then gave back its gains. HRMY rose into early September on continued strength in the WAKIX franchise and enthusiasm around its pipeline, including BP-205 single-ascending-dose data and preparations for pitolisant lifecycle programs. However, the rally was not sustained.
The October CEO-transition announcement introduced execution and succession uncertainty, even as management emphasized continuity in strategy. Around the same time, softer market conditions for biopharmaceutical names and lingering concerns about WAKIX's long-term exclusivity and generic competition weighed on sentiment. The early-November earnings report, which highlighted solid demand but higher operating costs and an EPS decline, reinforced the shift toward a more defensive posture among investors over the trailing quarter.
HRMY Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape HRMY's trajectory. The formal handoff of the CEO role to Peter Anastasiou on January 1, 2027, and any strategic updates that follow will be closely monitored. Investors will also track whether WAKIX continues to deliver consistent net patient additions and whether the company can sustain its path toward exceeding $1 billion in annual revenue.
Clinical and regulatory milestones remain central. Key watchpoints include the Pitolisant GR New Drug Application, which carries a PDUFA date of April 1, 2027, Phase 1b data for BP-205 in sleep-deprived healthy volunteers expected in the first quarter of 2027, and the initiation of Phase 2 studies planned for mid-2027. Ongoing patent litigation over the pitolisant franchise, with rulings expected around early 2027, will also influence the long-term revenue outlook. As with any biopharmaceutical investment, clinical setbacks, regulatory delays, and shifting payer dynamics remain meaningful risks. From what I see, these milestones will be critical to monitor closely in the months ahead.
Exploring AI Tools for Market Insights
In my regular research process, I turn to Tickeron’s AI tools to cross-check trends and compare positioning across similar names. One resource that stands out is the platform’s selection of AI-powered trading bots, which draw from a broad set of strategies applied to thousands of tickers. These bots differ in approach, time horizon, and performance, allowing users to evaluate what is currently gaining traction without relying on a single method. This kind of data-driven view can add useful context when assessing names like HRMY alongside broader sector moves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HRMY's RSI Oscillator ascending out of oversold territory
The RSI Indicator for HRMY moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 27 of the 31 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for HRMY just turned positive on October 28, 2026. Looking at past instances where HRMY's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Following a +0.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in 206 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
HRMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 60 cases where HRMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRMY as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
HRMY moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HRMY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for HRMY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.006) is normal, around the industry mean (3.051). P/E Ratio (10.995) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (2.581) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the role of asset allocation in my investments?
What is Lifetime Cost?
Top 5 AI Trading Bots for Strategic Investment and Navigating Market Volatility
AI Trading Agents (TSLA, GOOG, WMT): Outperforming Buy and Hold
FAQ: How is the 'distance to target' calculated in trend prediction engine (TPE)?
General Information
a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders
Industry Biotechnology
Advertisement